These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34671427)

  • 1. Short 57 kb
    Oyama Y; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Nabeshima K
    Oncol Lett; 2021 Dec; 22(6):813. PubMed ID: 34671427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low homozygous/high heterozygous deletion status by p16 FISH correlates with a better prognostic group than high homozygous deletion status in malignant pleural mesothelioma.
    Hamasaki M; Matsumoto S; Abe S; Hamatake D; Kamei T; Hiroshima K; Kawahara K; Sato A; Tsujimura T; Nakatani Y; Yoshida Y; Iwasaki A; Nabeshima K
    Lung Cancer; 2016 Sep; 99():155-61. PubMed ID: 27565933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDKN2A and MTAP Are Useful Biomarkers Detectable by Droplet Digital PCR in Malignant Pleural Mesothelioma: A Potential Alternative Method in Diagnosis Compared to Fluorescence
    Cheng YY; Yuen ML; Rath EM; Johnson B; Zhuang L; Yu TK; Aleksova V; Linton A; Kao S; Clarke CJ; McCaughan BC; Takahashi K; Lee K
    Front Oncol; 2020; 10():579327. PubMed ID: 33304846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.
    Illei PB; Rusch VW; Zakowski MF; Ladanyi M
    Clin Cancer Res; 2003 Jun; 9(6):2108-13. PubMed ID: 12796375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorescence in situ hybridization detection of chromosome 22 monosomy in pleural effusion cytology for the diagnosis of mesothelioma.
    Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Iwasaki A; Nabeshima K
    Cancer Cytopathol; 2021 Jul; 129(7):526-536. PubMed ID: 33493384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.
    Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Sato A; Tsujimura T; Ueda H; Makihata S; Kato F; Iwasaki A; Nabeshima K
    Lung Cancer; 2018 Nov; 125():198-204. PubMed ID: 30429020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma.
    Kinoshita Y; Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Hiroshima K; Oda Y; Nabeshima K
    Cancer Cytopathol; 2018 Jan; 126(1):54-63. PubMed ID: 29053210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Combination of MTAP and p16 Immunohistochemistry Can Substitute for CDKN2A Fluorescence In Situ Hybridization in Diagnosis and Prognosis of Pleural Mesotheliomas.
    Brcic L; Le Stang N; Gallob F; Pissaloux D; Sequeiros R; Paindavoine S; Pairon JC; Karanian M; Dacic S; Girard N; Churg A; Tirode F; Galateau-Salle F
    Arch Pathol Lab Med; 2023 Mar; 147(3):313-322. PubMed ID: 35738002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
    Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Iwasaki A; Nabeshima K
    Lung Cancer; 2019 Apr; 130():187-193. PubMed ID: 30885343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.
    Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
    Lung Cancer; 2017 Feb; 104():98-105. PubMed ID: 28213009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology.
    Matsumoto S; Nabeshima K; Kamei T; Hiroshima K; Kawahara K; Hata S; Marukawa K; Matsuno Y; Taguchi K; Tsujimura T
    Cancer Cytopathol; 2013 Aug; 121(8):415-22. PubMed ID: 23450849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma.
    Brich S; Bozzi F; Perrone F; Tamborini E; Cabras AD; Deraco M; Stacchiotti S; Dagrada GP; Pilotti S
    Mod Pathol; 2020 Feb; 33(2):217-227. PubMed ID: 31570769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma.
    Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Iwasaki A; Nabeshima K
    Mod Pathol; 2020 Feb; 33(2):235-244. PubMed ID: 31231129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Immunohistochemistry, Next-generation Sequencing and Fluorescence In Situ Hybridization for Detection of MTAP Loss in Pleural Mesothelioma.
    Febres-Aldana CA; Chang JC; Jungbluth AA; Adusumilli PS; Bodd FM; Frosina D; Geronimo JA; Hernandez E; Irawan H; Offin MD; Rekhtman N; Travis WD; Vanderbilt C; Zauderer MG; Zhang Y; Ladanyi M; Yang SR; Sauter JL
    Mod Pathol; 2024 Mar; 37(3):100420. PubMed ID: 38185249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of methylthioadenosine phosphorylase (MTAP) protein expression with MTAP and CDKN2A copy number in malignant pleural mesothelioma.
    Chapel DB; Dubuc AM; Hornick JL; Sholl LM
    Histopathology; 2021 Jun; 78(7):1032-1042. PubMed ID: 33387364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges and limitation of MTAP immunohistochemistry in diagnosing desmoplastic mesothelioma/sarcomatoid pleural mesothelioma with desmoplastic features.
    Sa-Ngiamwibool P; Hamasaki M; Kinoshita Y; Matsumoto S; Sato A; Tsujimura T; Kasai T; Hiroshima K; Kushitani K; Takeshima Y; Kawahara K; Iwasaki A; Nabeshima K
    Ann Diagn Pathol; 2022 Oct; 60():152004. PubMed ID: 35797798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure.
    Kettunen E; Savukoski S; Salmenkivi K; Böhling T; Vanhala E; Kuosma E; Anttila S; Wolff H
    BMC Cancer; 2019 May; 19(1):507. PubMed ID: 31138176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
    McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
    Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival.
    Krasinskas AM; Bartlett DL; Cieply K; Dacic S
    Mod Pathol; 2010 Apr; 23(4):531-8. PubMed ID: 20081810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens.
    Berg KB; Churg AM; Cheung S; Dacic S
    Cancer Cytopathol; 2020 Feb; 128(2):126-132. PubMed ID: 31821740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.